Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. (2016). http://globocan.iarc.fr
  Google Scholar
• 2. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
  MedlineGoogle Scholar
• 3. Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol. 1, 505–527 (2015).
  MedlineGoogle Scholar
• 4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403 (2013).
  Medline CASGoogle Scholar
• 5. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67, 519–530 (2015).
  MedlineGoogle Scholar
• 6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016).
  MedlineGoogle Scholar
• 7. Saad AM, Gad MM, Al-Husseini MJ et al. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin. Genitourin. Cancer 17, 46–57 (2019).
  MedlineGoogle Scholar
• 8. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur. Urol. 70, 93–105 (2016).
  MedlineGoogle Scholar
• 9. McLaughlin J, Lipworth L, Tarone R, Blot W. Cancer Epidemiology and Prevention (3rd Edition). In: Kidney Cancer. Schottenfeld DFraumeni JF (Eds). Oxford University Press, Oxford, UK, 1087–1100 (2006).
  Google Scholar
• 10. Hsieh JJ, Purdue MP, Signoretti S et al. Renal cell carcinoma. Nat. Rev. Dis. Primers 3, 17009, (2017).
  MedlineGoogle Scholar
• 11. Lerner SP, Linehan WM, Rathmell WK. Kidney cancer. Urol. Oncol. 30, 948–951 (2012).
  MedlineGoogle Scholar
• 12. Grignon DJ, Che M. Clear cell renal cell carcinoma. Clin. Lab. Med. 25(2), 305–316 (2005).
  MedlineGoogle Scholar
• 13. Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 7, 307 (2018).
  MedlineGoogle Scholar
• 14. Garfield K, LaGrange CA. Cancer, Renal Cell. In: StatPearls. StatPearls Publishing, FL, USA (2020).
  Google Scholar
• 15. Kaelin WG. von Hippel-Lindau disease. Annu. Rev. Pathol. 2, 145–173 (2007).
  Medline CASGoogle Scholar
• 16. Kapitsinou PP, Haase VH. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ. 15, 650–659 (2008).
  Medline CASGoogle Scholar
• 17. Wei EY, Hsieh JJ. A river model to map convergent cancer evolution and guide therapy in RCC. Nat. Rev. Urol. 12, 706–712 (2015).
  Medline CASGoogle Scholar
• 18. Pena-Llopis S, Rubin de Celis SV, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751–759 (2012).
  Medline CASGoogle Scholar
• 19. Hakimi AA, Chen YB, Wren J et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol. 63, 848–854 (2013).
  MedlineGoogle Scholar
• 20. Sato Y, Yoshizato T, Shiraishi Y et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860–867 (2013).
  Medline CASGoogle Scholar
• 21. Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat. Genet. 45, 849–850 (2013).
  Medline CASGoogle Scholar
• 22. Grange C, Tapparo M, Collino F et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71, 5346e56 (2011).
  Google Scholar
• 23. Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: biology and implications for therapy. Asian J. Urol. 3, 286–292 (2016).
  MedlineGoogle Scholar
• 24. Lopez-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene 32, 1752e60 (2013).
  Google Scholar
• 25. Razorenova OV, Finger EC, Colavitti R et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{d}-driven migration. Proc. Natl Acad. Sci. USA 108, 1931e6 (2011).
  Google Scholar
• 26. Aubert S, Fauquette V, Hemon B et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 69, 5707e15 (2009).
  Google Scholar
• 27. Struckmann K, Mertz K, Steu S et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J. Pathol. 214, 464e71 (2008).
  Google Scholar
• 28. National Comprehensive Cancer Network clinical practice guidelines: renal cell carcinoma. (2020) www. nccn.org
  Google Scholar
• 29. Rini BI, Pal SK, Escudier BJ et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a Phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 21(1), 95–104 (2020). •• TIVO-3 was a pivotal Phase III trial that demonstrated superior efficacy, progression-free survival (PFS) and safety of tivozanib compared with sorafenib in patients with advanced renal cell carcinoma (RCC) that had progressed after treatment with multiple systemic therapies.
  Medline CASGoogle Scholar
• 30. Molina AM, Hutson TE, Nosov D et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a Phase 3 study. Eur. J. Cancer 94, 87–94 (May 2018). •• Illustrated the significant confounding of the overall survival results of the TIVO-1 trial.
  Medline CASGoogle Scholar
• 31. Pal SK, Choueiri TK, Karam JA, Heng DY. Metastatic renal cell carcinoma: contending with a sea change in therapy. Urol. Oncol. 33, 507e8 (2015).
  Google Scholar
• 32. Grimm MO, Leucht K, Grünwald V, Foller S. New first line treatment options of clear cell renal cell cancer patients with PD-1 or PD-L1 immune checkpoint inhibitor-based combination therapies. J. Clin. Med. 9(2), E565, (2020).
  Medline CASGoogle Scholar
• 33. Ornstein MC, Pal SK, Wood LS et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 20, 1386–1394 (2019).
  Medline CASGoogle Scholar
• 34. Ljungberg B, Albiges L, Bensalah K et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. Eur. Urol. 75(5), 799–810 (2019).
  MedlineGoogle Scholar
• 35. Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J. Clin. Oncol. 31, 3791–3799 (2013). •• An incredibly important TIVO-1 Phase III study that first showed the superior efficacy and safety of tivozanib versus sorafenib. Guided the European Medicines Agency's approval of tivozanib in the EU.
  Medline CASGoogle Scholar
• 36. Sánchez-Gastaldo A, Kempf E, González Del Alba A, Duran I. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat. Rev. 60, 77–89 (2017). • A comprehensive review of the available treatment strategies to combat RCC.
  Medline CASGoogle Scholar
• 37. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr. Oncol. Rep. 13, 103–111 (2011).
  Medline CASGoogle Scholar
• 38. Nakamura K, Taguchi E, Miura T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 66(18), 9134–9142 (2006).
  Medline CASGoogle Scholar
• 39. Kumar R, Crouthamel MC, Rominger DH. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101(10), 1717–1723 (2009).
  Medline CASGoogle Scholar
• 40. Gupta Shilpa, Fishman Mayer. Progress and contrasts of the development of tivozanib for therapy of kidney cancer. Expert Opin. Pharmaco. 12(18), 2915–2922 (2011).
  Medline CASGoogle Scholar
• 41. Eskens FA, de Jonge MJ, Bhargava P et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin. Cancer Res. 17, 7156–7163 (2011).
  Medline CASGoogle Scholar
• 42. Cotreau MM, Hale C, Jacobson L. Absorption, metabolism, and excretion of [¹⁴C]-tivozanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in healthy male participants: a Phase I, open-label, mass-balance study. Clin. Pharmacol. Drug Dev. 1(3), 102–109 (2012). • This Phase I study helped to elucidate the absorption, metabolism and excretion mechanics of tivozanib.
  MedlineGoogle Scholar
• 43. Cotreau MM, Massmanian L, Strahs AL, Slichenmyer W, Vargo DL. The effect of food on the pharmacokinetics of tivozanib hydrochloride. Clin. Pharmacol. Drug Dev. 3, 158–162 (2014). • This Phase I study helped to show that the distribution and elimination of tivozanib are unchanged by the consumption of food.
  Medline CASGoogle Scholar
• 44. Cotreau M, Subic D, Massmanian L, Strahs A, Vargo D. The effect of rifampin on the pharmacokinetics of tivozanib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. Eur. J. Cancer 48(Suppl. 6), 183 (2012). • This Phase I study helped to show that inhibitors of CYP3A4 like ketoconazole do not change the pharmacokinetic properties of tivozanib, but inducers of the CYP3A4 pathway like rifampin do.
  Google Scholar
• 45. Eskens FA, de Jonge MJ, Bhargava P et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin. Cancer Res. 17(22), 7156–7163 (2011). • Established the recommended treatment dosing of tivozanib at 1.5 mg orally daily in a ‘3 week on, 1 week off’ cycle.
  Medline CASGoogle Scholar
• 46. Escudier, B, Porta C, Eisen T et al. The role of tivozanib in advanced renal cell carcinoma therapy. Expert Rev. Anticancer Ther. 18(11), 1113–1124 (2018).
  Medline CASGoogle Scholar
• 47. Fishman MN, Srinivas S, Hauke RJ et al. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. Eur. J. Cancer 49, 2841–2850 (2013). • Important Phase Ib trial that showed the efficacy of a tivozanib and temsirolimus combination.
  Medline CASGoogle Scholar
• 48. Nosov DA, Esteves B, Lipatov ON et al. Antitumor activity and safety of tivozanib (AV-951) in a Phase II randomized discontinuation trial in patients with renal cell carcinoma. J. Clin. Oncol. 30, 1678–1685 (2012). • Important Phase II trial on tivozanib.
  Medline CASGoogle Scholar
• 49. Hutson TE, Rathmell WK, Feng B et al. Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma. Presented at: The European Society for Medical Oncology Annual Congress. Madrid, Spain, 26–30 September 2014 • Important Phase II trial that elucidated important biomarkers and a mechanism of resistance to tivozanib.
  Google Scholar
• 50. Santoni M, Massari F, Piva F et al. Tivozanib for the treatment of renal cell carcinoma. Expert Opin. Pharmacother. 19(9), 1021–1025 (2018).
  Medline CASGoogle Scholar
• 51. Needle MN, Hutson TE, Motzer RJ. The effect of geography and the availability of second-line therapy on overall survival in a one-way crossover design study in renal cell carcinoma. J. Clin. Oncol 34(15), e16120 (2017). •• Explained further the confounding impact of geography and local accessibility to second-line treatments on the overall survivalresults of the TIVO-1 study.
  Google Scholar
• 52. Pal SK, Escudier B, Atkins MB et al. TIVO-3: final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC). Presented at: 2020 ASCO Virtual Program, 27 May 2020.
  Google Scholar
• 53. European Medicines Agency. Fotivda: European public assessment report. (2017). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_ report/human/004131/WC500239035.pdf
  Google Scholar
• 54. Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC. 11, 172–191 (2013).
  MedlineGoogle Scholar
• 55. Staehler M, Spek A, Rodler S et al. Real-world results from one year of therapy with tivozanib. Kidney Cancer. 3, 1–5 (2019).
  Google Scholar
• 56. Wong S, Prasad K, Waddell T et al. Tivozanib as first-line treatment of metastatic renal cell carcinoma: a real-world outcome review in North-West of England, United Kingdom. J. Clin. Oncol. 38(Suppl. 6), 638–638 (2020).
  Google Scholar